跳至主要内容
临床试验/NCT07269392
NCT07269392尚未招募4 期

Impact of Dual Trigger Using Recombinant Human Chorionic Gonadotropin (HCG) and Gonadotropin-releasing Hormone (GnRH) Agonist on Thawed Modified Natural Cycle Outcomes: an Open-label Multi-center Randomized Controlled Trial.

National Taiwan University Hospital0 个研究点目标入组 170 人开始时间: 2026年1月1日最近更新:
干预措施

试验速览

阶段
4 期
状态
尚未招募
入组人数
170
主要终点
Implantation

研究概览

简要总结

Impact of dual trigger using recombinant human chorionic gonadotropin (HCG) and gonadotropin-releasing hormone (GnRH) agonist on thawed modified natural cycle outcomes: an open-label multi-center randomized controlled trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
25 Years 至 44 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • 1. 24<= Age < 45 patient undergo mNC-FET

排除标准

  • 1. Congenital or acquired uterine abnormalities (uterine malformation, submucosal myoma, intrauterine adhesion or endometrial polyp >1cm)

研究组 & 干预措施

dual

Experimental

GnRH agonist

干预措施: GnRH agonist (Drug)

结局指标

主要结局

Implantation

时间窗: 14 days after embryo transfer

Implantation is defined as a positive serum β-hCG (\>20 mIU/mL) measured 14 days after embryo transfer.

次要结局

  • Clinical pregnancy(one week after confirm pregnancy)
  • Miscarriage rate(before delivery)
  • Live birth rate(delivery)
  • Gestational age (weeks) at delivery(delivery)
  • Birth weight(delivery)
  • Ongoing pregnancy rate(5 weeks after confirmed pregnancy)
  • Presence of significant congenital or medical conditions of the newborn(delivery)

研究者

申办方类型
Other
责任方
Sponsor

相似试验